Abstract
We administered ketamine to schizophrenic individuals in a double-blind, placebo-controlled design using a range of subanesthetic doses (0.1, 0.3, and 0.5 mg/kg) to evaluate the nature, dose characteristics, time course, and neuroleptic modulation of N-methyl-D-aspartate (NMDA) antagonist action on mental status in schizophrenia. Ketamine induced a dose-related, short (< 30 minutes) worsening in mental status in the haloperidol-treated condition, reflected by a significant increase in BPRS total score for the 0.3 mg/kg (p =. 005) and 0.5 mg/kg (p =. 01) challenges. Positive symptoms (hallucinations, delusions, thought disorder), not negative symptoms accounted for these changes. These ketamine-induced psychotic symptoms were strikingly reminiscent of the subject's symptoms during active episodes of their illness. Results from six patients who were retested in the same design after being neuroleptic-free for 4 weeks failed to indicate that haloperidol blocks ketamine-induced psychosis. Several subjects evidenced delayed or prolonged (8–24 hours) psychotomimetic effects such as worsening of psychosis with visual hallucinations. These data suggest that antagonism of NMDA-sensitive glutamatergic transmission in brain exacerbates symptoms of schizophrenia.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lahti, A., Koffel, B., LaPorte, D. et al. Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia. Neuropsychopharmacol 13, 9–19 (1995). https://doi.org/10.1016/0893-133X(94)00131-I
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/0893-133X(94)00131-I
Keywords
This article is cited by
-
Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry
Neuropsychopharmacology (2024)
-
Targeting synapse function and loss for treatment of neurodegenerative diseases
Nature Reviews Drug Discovery (2024)
-
Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS
Scientific Reports (2023)
-
Hydrogen sulfide and polysulfides induce GABA/glutamate/d-serine release, facilitate hippocampal LTP, and regulate behavioral hyperactivity
Scientific Reports (2023)
-
Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation
Molecular Psychiatry (2023)